$2.89
+4.71%Oct 8, 2026, 05:00 UTC
Neurosterix announced plans to advance NTX-253 into Phase 2 clinical development.
Source:Oct 8, 2026, 05:00 UTC
Neurosterix completed Phase 1 clinical studies evaluating NTX-253.
Source:Oct 2, 2026, 05:00 UTC
Mikhail Kalinichev stepped down as Head of Translational Science at Addex Therapeutics.
Source:Oct 2, 2026, 05:00 UTC
Addex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and member of the Executive Management.
Source:Sep 28, 2026, 05:00 UTC
Addex Therapeutics reported its 2026 half-year and second quarter financial results and provided a corporate update.
Source:Sep 24, 2026, 05:00 UTC
Addex Therapeutics announced it will report its 2026 half-year and second-quarter financial results on September 28, 2026, with a conference call hosted by CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev.
Source:Aug 26, 2026, 05:00 UTC
Addex Therapeutics raised USD 2.8 million in gross proceeds through the sale of 437,869 ADSs under its At the Market offering agreement.
Source: